Viatris offered little in the way of detail as it announced a setback for its Mapi Pharma-partnered proposed once-monthly glatiramer acetate product for relapsing forms of multiple sclerosis. The firm has previously shouted from the rooftops about Mapi’s Phase III clinical study and the potential to establish a new standard of care for glatiramer acetate patients.

Fresh from a $20m investment from partner Viatris, Mapi Pharma has announced significant progress in its Phase III trial for a long-acting version of Copaxone, which is to be filed through the FDA’s 505(b)(2) hybrid pathway.

Pharma pays $100m up front and makes $20m equity investment for rights to three preclinical cancer programs. Plus more than 20 deal summaries, including COVID-19-related transactions.

Mylan has invested a further $20m in a monthly glatiramer acetate depot product being developed by partner Mapi for submission via the 505(b)(2) route in the US.